Odronextamab
- Generic Name
- Odronextamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801338-64-6
- Unique Ingredient Identifier
- 8R5CM46UIO
- Background
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL). Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however...
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02651662
- Locations
- 🇦🇹
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III, Salzburg, Austria
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇺🇸University of California Los Angeles Medical Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath